Obesity Clinical Trial
Official title:
Comparison of the Effects of Brain Function Changes on Body Weight After Intragastric Balloon Surgery and Sleeve Gastric Surgery
This is a prospective, single-center, randomized, open-label, parallel-controlled clinical trial to compare the changes in brain function after intragastric balloon and sleeve gastrectomy.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | December 1, 2022 |
Est. primary completion date | November 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 18 = age = 65, regardless of gender; - BMI = 27.5kg/m2 and = 40kg / m2; - Those who have tried other weight loss methods in the past but are not satisfied with the results; - Willingness to comply with the study requirements, including willingness to avoid the use of drugs or other substances for weight loss during the follow-up study; - Right handed, avoid using antibiotics and probiotics within 3 month before enrollment; - Be able to take proton pump inhibitors and antiemetics according to the regulations of the researcher; - It can walk completely independently without any serious chronic orthopedic diseases; - Be willing to avoid the use of non-steroidal anti-inflammatory drugs during the study, including aspirin, diclofenac, ibuprofen, naproxen or other known gastric irritants; - Willing to accept gastroscopy; - Voluntarily participate in the trial and sign the informed consent form. Exclusion Criteria: - Patients with previous or current diagnosis of ketoacidosis; - Symptomatic congestive heart failure, arrhythmia or unstable coronary artery disease; - Currently suffering from respiratory diseases such as chronic obstructive pulmonary disease (COPD), pneumonia or lung cancer; - Have undergone weight loss surgery before enrollment in the study, or may have undergone weight loss surgery during the study; - Before the study, he used intragastric medical devices to lose weight; - Had acute or chronic pancreatitis within 12 months before enrollment; - Previous or current history of small bowel obstruction - Obesity caused by genetic endocrine reasons (test results of cortical hormone and thyroid hormone, clinically significant abnormalities determined by the researcher) and not fully controlled by drugs; - Esophageal, gastric or duodenal diseases (including hiatal hernia (= 2cm), paraesophageal hernia, polyps, acute erosive gastritis, cancer, varices, diverticulum, gastroparesis, ulcer, stenosis, achalasia of cardia complicated with esophagitis, etc.); - Systemic corticosteroid anticoagulants (such as warfarin, dabigatran or antiplatelet drugs), immunosuppressive drugs (such as imidazole thiopurine, cyclosporine), prescription or over-the-counter weight loss drugs, drugs known to cause significant weight gain or weight loss, such as anesthetics, opioids or diazepines), insulin Antiepileptic drugs (such as clonazepam and phenytoin sodium), antiarrhythmic drugs (such as amiodarone); Other drugs that may cause weight change include: drugs that can significantly increase weight (such as glucocorticoids, insulin secretagogues, thiazolidinediones, atypical antipsychotics, sodium valproate, lamotrigine, antidepressants), and drugs that can significantly reduce weight (such as glucagon like peptide-1 receptor agonists a- Glucosidase inhibitor, zonisamide, topiramate, fluoxetine, bupropion, etc.); - Night eating syndrome or bulimia; - Unwilling to avoid any reconstruction and / or plastic surgery that may affect body weight during the study, such as mastoplasty and liposuction; - Patients with inflammatory bowel disease (such as Crohn's disease and ulcerative colitis); - Previous history of malignant tumor; - Women of childbearing age whose pregnancy test is not negative before examination, lactating women, or who plan to conceive within half a year; - Past or current drug or alcohol abuse. |
Country | Name | City | State |
---|---|---|---|
China | The Third Xiangya Hospital of Central South University | Changsha | Hunan |
Lead Sponsor | Collaborator |
---|---|
The Third Xiangya Hospital of Central South University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean overall weight loss response rate | (Weight loss / total weight before treatment × 100%=5%) number of subjects / total number of subjects × 100% | 16 weeks after operation | |
Secondary | Mean total weight loss percentage of subjects(%TWL) | Weight loss / total weight before treatment × 100% | The 16th, 24th and 32nd weeks after operation | |
Secondary | Weight loss maintenance | Weight loss and maintenance of subjects | The 16th, 24th and 32nd weeks after operation | |
Secondary | Impact Of Weight On Quality Of Life-Lite (IWQOL-Lite) Questionnaire | Change in obesity-specific health-related quality of life as measured by Impact Of Weight On Quality Of Life-Lite (IWQOL-Lite) Questionnaire total score from baseline to 32 weeks Minimum 0 Maximum 100 Higher score means better | The 16th, 24th and 32nd weeks after operation | |
Secondary | Questionnaire | Evaluation of postoperative appetite related questionnaire(the Hospital Anxiety and Depression Scale, the Three-Factor Eating Questionnaire R21, the Yale Food Addiction Scale 2.0) | Preoperative and postoperative weeks 16, 24 and 32 | |
Secondary | Gastrointestinal hormone | Changes of gastrointestinal hormone(ghrelin,leptin,cholecystokinin,adiponectin) levels after operation | Preoperative and postoperative weeks 16, 24 and 32 | |
Secondary | Brain function | Brain functional magnetic resonance imaging | Preoperative and postoperative weeks 16, 24 and 32 | |
Secondary | Correlation of fecal microbial profile with obesity | Analysis of fecal microbial profile using 16s rRNA sequencing | Preoperative and postoperative weeks 16, 24 and 32 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |